Actively Recruiting
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-13
36
Participants Needed
7
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
CONDITIONS
Official Title
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Obesity (BMI 30 kg/m2 or higher) OR Overweight (BMI 27 kg/m2 or higher) with at least one related health condition OR Type 2 Diabetes Mellitus with BMI 25 kg/m2 or higher
- Type 2 Diabetes Mellitus defined by history or blood sugar criteria
- New diagnosis of stage I-III endometrial cancer
- Completed surgery with total hysterectomy and bilateral salpingo-oophorectomy with no gross residual disease
- Recommended for curative chemotherapy with carboplatin and paclitaxel for 4-6 cycles, with or without radiation
- Eligible histologic epithelial cell types as specified
- Adequate organ function by laboratory values
- Insurance approval or willingness to pay for tirzepatide or semaglutide for study duration
- Ability and willingness to learn and perform self-injection or have trained assistance
- Not pregnant and not nursing
- English speaking or have an English-speaking family member/caregiver to assist with dietary tracking
You will not qualify if you...
- Known Type 1 diabetes
- Presence of GAD, Islet Cell, or Zn Transporter 8 antibodies
- History of gastroparesis
- High risk for aspiration
- Active or past pancreatitis
- History of elevated calcitonin
- Personal or family history of Medullary Thyroid Carcinoma with Multiple Endocrine Neoplasia-2 syndrome
- Prior surgical, endoscopic, or device-based obesity therapy within past 2 years
- Removal of device-based obesity therapy within last 6 months
- Current use or prior intolerance of GIP/GLP-1 or GLP-1 receptor agonists
- Prior or concurrent malignancy interfering with study safety or efficacy
- Known intolerance to the study drug or its components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Commack
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
S
Sminu Bose, MD
CONTACT
L
Lubaina Presswala, DO
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here